3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Malignancies
1
Interventions
pembrolizumab
47
Nivolumab
34
Sunitinib
18
Cyclophosphamide
18
Everolimus
17
Ipilimumab
15
cabozantinib
14
pazopanib
13
Bevacizumab
13
fludarabine
12
atezolizumab
11
temsirolimus
10
Magnetic Resonance Spectroscopy
10
Sorafenib
9
aldesleukin
8
Specimen Handling
8
Paclitaxel
8
Sirolimus
7
CTLA-4 Antigen
7
Axitinib
7
belzutifan
6
Radiosurgery
6
Oxaliplatin
6
Interleukin-2
6
Fluorouracil
6
spartalizumab
5
avelumab
5
Leucovorin
5
Irinotecan
5
Docetaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Renal Cell
×
Tiragolumab
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled